Serving To Educate Primary Care Clinicians On Metabolic Issues
Evidence Based Medicine Header 1
Medical Education Header 2
Peer-to-peer Exchange Header 3
Metabolic Diseases Header 4
News: Consultant 360 Metabolic Disease Articles June 2019

New Metabolic Disease Articles from our Partners at Consultant 360

One-Third of Statin Users Do Not Reach Healthy LDL-C Levels

http://bit.ly/2VZf9GM

New research suggests a large proportion of statin-treated patients may not meet appropriate LDL-C thresholds and remain at-risk for CVD events, indicating “an unmet preventive need.”

Diabetes Is an Independent Predictor of Advanced Liver Disease

http://bit.ly/2I8XbJg

Because of the common nature of non-alcoholic fatty liver disease and the chance of progression to non-alcoholic steatohepatitis, cirrhosis, and hepatocellular carcinoma, researchers sought to estimate the risk of acquiring advanced liver disease and identify potential predictors of disease progression.

Liraglutide Improves Glycemic Control in Youth With Diabetes

http://bit.ly/2VTjirH

While metformin is the most common treatment of choice in children with type 2 diabetes, early loss of glycemic control has been observed with metformin monotherapy.

Common Diabetes Drug Class Linked to Rare Form of Gangrene

http://bit.ly/2I9oNxA

Previous research has indicated that use of sodium-glucose cotransporter-2 inhibitors could be associated with a rare urologic necrotizing infection. In a recent analysis, the FDA sought to further examine this relationship.

ADA Updates Recommendations for Diabetes and Chronic Kidney Disease

http://bit.ly/2QLmYem

In response to results from a placebo-controlled trial on the use of sodium-glucose cotransporter 2 inhibitors in patients with diabetes and chronic kidney disease, the ADA has released new updates to their Living Standards of Medical Care in Diabetes.